B-Vitamins Reduce the Long-Term Risk of Depression After Stroke: The VITATOPS-DEP Trial

被引：81

作者：

Almeida, Osvaldo P. ^{[1
,2
,4
]}

Marsh, Kylie ^{[2
]}

Alfonso, Helman ^{[2
]}

Flicker, Leon ^{[2
,3
,5
]}

Davis, Timothy M. E. ^{[3
,7
]}

Hankey, Graeme J. ^{[3
,6
]}

机构：

[1] Univ Western Australia, WA Ctr Hlth & Ageing M573, Sch Psychiat & Clin Neurosci, Perth, WA 6009, Australia

[2] Univ Western Australia, Western Australia Ctr Hlth & Ageing, Med Res Ctr, Perth, WA 6009, Australia

[3] Univ Western Australia, Sch Med & Pharmacol, Perth, WA 6009, Australia

[4] Royal Perth Hosp, Dept Psychiat, Perth, WA, Australia

[5] Royal Perth Hosp, Dept Geriatr Med, Perth, WA, Australia

[6] Royal Perth Hosp, Dept Neurol, Perth, WA, Australia

[7] Fremantle Hosp, Dept Med, Freernantle, Australia

来源：

ANNALS OF NEUROLOGY | 2010年 / 68卷 / 04期

基金：

英国医学研究理事会;

关键词：

FOLIC-ACID; DOUBLE-BLIND; POSTSTROKE DEPRESSION; RANDOMIZED-TRIAL; OLDER MEN; FOLLOW-UP; HOMOCYSTEINE; ASSOCIATION; PREVENTION; FOLATE;

D O I：

10.1002/ana.22189

中图分类号：

R74 [神经病学与精神病学];

学科分类号：

摘要：

Objective: The consumption of certain B-vitamins through diet or supplementation decreases the total plasma concentration of homocysteine (tHcy) and may enhance response to standard antidepressant treatment. It is unclear if treatment with B-vitamins can reduce the long-term prevalence of depression in people at risk, such as stroke survivors. The purpose of this research was to determine if treatment with B-vitamins reduces the hazard of poststroke depression compared with placebo. Methods: Randomized, double-blind, placebo-controlled trial of tHcy-lowering treatment with daily folic acid (2 mg), vitamin B6 (25 mg), and vitamin B12 (0.5 mg) for 1 to 10.5 years in survivors of stroke. The primary endpoint was the onset of Diagnostic and Statistical Manual of Mental Disorders, 4th edition (DSM-IV) major depression after randomization. Secondary outcomes were the prevalence of DSM-IV major or minor depression at the end of treatment. Other measured factors included age, gender, poststroke handicap associated with stroke, recurrence of strokes, cognitive impairment, and use of antidepressants. Results: Among 273 people who completed the final assessment after 7.1 +/- 2.1 years (mean standard deviation) of follow up, random assignment to B-vitamins was associated with a lower hazard of major depression compared with placebo (18.4% vs 23.3%, adjusted hazard ratio [HR] = 0.48; 95% confidence interval [Cl] = 0.31-0.76) and a trend toward a lower odds of major or minor depression at the end of the trial compared with placebo (19.1% vs 27.7%; adjusted odds ratio [OR] = 0.58; 95%CI = 0.31-1.09). Interpretation: Long-term treatment of poststroke survivors with folic acid, B6, and B12 was associated with a reduction in the hazard of major depression in our patient population. If these findings can be validated externally, B-vitamin supplementation offers hope as an effective, safe, and affordable intervention to reduce the burden of poststroke depression. ANN NEUROL 2010;68:503-510

引用

页码：503 / 510

页数：8

共 45 条

[1] Contribution of the MTHFR gene to the causal pathway for depression, anxiety and cognitive impairment in later life [J].